| abstract |
REFERS TO THE USE OF a) AN ANTIOXIDANT SUCH AS VITAMIN A, VITAMIN E, VITAMIN C, COENZYME Q10, BUTYLATED HYDROXIANISOL (BHA), BUTYLATED HYDROXYTOLUENE (BHT), N-ACETYL CYSTEIN, SELENIUM, PANATI-VIRI (4-ISOPYL-4 2,6-DI-t-BUTYLPHENOL), SILYBUM MARIANUM, LYCOPENE; a, d-ALPHA TOCOPHERYL ESTER, ALPHA-TOCOPHERYL POLYETHYLENE GLYCOL SUCCINATE ESTER, TO IMPROVE RIBAVIRIN-RELATED HEMOLYSIS; b) A THERAPEUTICALLY AMOUNT OF RIBAVIRIN ENOUGH TO LOWER THE DETECTABLE VIRAL RNA. IT ALSO REFERS TO THE USE OF A COMBINATION OF 600 mg / DAY TO 1600 mg / DAY OF RIBAVIRIN WITH INTERFERON ALPHA 2a OR 2b TREATED WITH PEG OR A CONCENSUAL INTERFERON OR A PURIFIED INTERFERON ALPHA PRODUCT; FOR A FIRST PERIOD OF 24 WEEKS; THEN THE USE OF 600 mg / DAY TO 1600 mg / DAY OF RIBAVIRIN WITH THE ANTIOXIDANT FOR A SECOND PERIOD OF 24 WEEKS; MAY BE USEFUL FOR THE TREATMENT OF CHRONIC HEPATITIS C INFECTIONS |